Page 'Breadcrumb' Navigation:
Dr. Mahesh V. Patel has more than 20 years of technology and product development experience in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, Dr. Patel led drug delivery research and development at Pharmacia and Upjohn in Kalamazoo, MI. He received his MS in Physical Pharmacy at the University of Cincinnati and his PhD in Pharmaceutics from the University of Utah. His areas of expertise include strategic planning, technology assessment/development, technical management and product research and development.
Mr. Morgan Brown has more than 20 years of finance and accounting experience with the last thirteen years servicing biotechnology, pharmaceutical, medical device and clinical research companies. Prior to joining Lipocine, Mr. Brown served in a similar capacity at Innovus Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceuticals company, at World Heart Corporation (NASDAQ: WHRT), a medical device company, and Lifetree Clinical Research, a clinical research organization. During Mr. Brown's tenure at World Heart Corporation, he was involved in numerous financings in addition to the ultimate sale of World Heart Corporation to Heartware International Inc. (NASDAQ: HTWR). Previously he worked for NPS Pharmaceuticals Inc. (NASDAQ: NPSP), a biotechnology company where he served as Vice President Finance and Treasurer. During his tenure at NPS Pharmaceuticals, Inc., Mr. Brown was involved in numerous financings as well as merger and acquisition activities. Before NPS Pharmaceuticals, Inc., Mr. Brown worked for KPMG LLP in Salt Lake City for over seven years and managed multiple audit engagements, servicing private and publicly owned clients. Mr. Brown is a licensed certified public accountant in Utah. Mr. Brown earned a Master of Science degree in Business Administration from the University of Utah and a Bachelor of Science degree in Accounting from Utah State University.
Mr. Bass brings over 20 years of pharmaceutical and biotech sales, marketing, market access and operations experience to Lipocine. He has a proven track record of launching new products, improving operating performance and driving value across a broad range of therapeutic categories which includes men’s health. Most recently, he was Lipocine’s Vice President of Market Access. Prior to joining Lipocine, Mr. Bass served as the Vice President of Market Access at Merz. Previously, he held multiple senior leadership roles in marketing and market access over a 9 year period at Johnson & Johnson. Before Johnson & Johnson, Mr. Bass spent 7 years at Pfizer and held positions of increasing responsibility in sales and operations. He received his bachelor’s degree in Biology from Brandeis University in Waltham, MA.
Dr. Mattila brings over 25 years of business development, commercial and general management experience to Lipocine. Prior to joining Lipocine, Dr. Mattila served as CBO of iCeutica Operations Inc. and as President and CEO of LZ Therapeutics, Inc. Prior to these positions, Dr. Mattila was Executive Vice President of Business Development, Product Development and Technical Operations at Auxilium Pharmaceutical, Inc and President of Orion Pharma, where under his leadership several innovative products were developed, partnered and commercialized for global markets. Dr. Mattila has negotiated and closed over 50 business agreements, including licensing, co-marketing, collaboration and product acquisition arrangements. He received his M.D. and Ph.D. in Pharmacology from the University of Helsinki Medical School and an M.B.A. from the Helsinki School of Economics.